Surfing The NASH Tsunami Podcast

Driving The Discussion In Fatty Liver Disease

Drug developers, investors, researchers, and corporate executives…

Every week, a global community of Fatty Liver Disease stakeholders comes together to explore the most important challenges in diagnosing, treating, and developing medications for patients with Fatty Liver Diseases.

Join hepatology researcher and Key Opinion Leader Dr. Stephen Harrison, liver wellness advocate Louise Campbell MSc AP., Forecasting and Pricing guru Roger Green, M.B.A., and their weekly guests as they discuss these issues from their own unique perspectives on the Surfing the NASH Tsunami podcast.

most recent episode ⤵

S3-E58 - Surfing 2022: NAFLD Year-in-Review
SurfingNASH.Com is honored to have the following sponsors

S3-E55 – 2022 AASLD Wrap-Up: Reviewing a Momentous Meeting

Jörn Schattenberg, William Alazawi, Naim Alkhouri, Laurent Castera, Kenneth Cusi, Wayne Eskridge and Roger Green convene to recap the just-concluded 2022 AASLD Liver Meeting. The panelists touch on a range of topics from a particularly momentous event which saw many promising papers presaging an exciting upcoming year for the field of Fatty Liver.

S3-E54.4 – An Interview with Michael Cooreman, CMO of Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology. In an exclusive interview, Chief Medical Officer Michael Cooreman joins Stephen Harrison and Roger Green to talk in depth about the company and key elements of its clinical development strategy for its pan-PPAR, lanifibranor.

S3-E54.3 – Exploring Mitochondrial Uncouplers in NASH and a Reanalysis of REGENERATE Study’s Phase 3 Results

Surfing the NASH Tsunami hosted two recording sessions throughout the Liver Meeting to discuss key takeaways. This conversation is a composite featuring impressions from both sessions. In the first session, panelists review the emerging role of mitochondrial uncouplers in the field of NASH. The following session offers insight from a reanalysis of results from Intercept’s Phase 3 REGENERATE Study of Obeticholic Acid.

S3-E54.2 – Presentation on Efruxifermin in NASH with Fibrosis

On the final morning of the 2022 AASLD Liver Meeting, Stephen Harrison, Sven Francque, Jörn Schattenberg, Ian Rowe, Jeff McIntyre and Roger Green discussed their key takeaways and impressions. Stephen leads this conversation to highlight his presentation of results from Akero Therapeutics’ Phase 2b HARMONY Study.

S3-E54.1 – Utilizing Best Practices in Diagnostics

The 73rd Annual AASLD Liver Meeting proved to be a lively and momentous event held in Washington DC. On the final morning, Stephen Harrison, Sven Francque, Jörn Schattenberg, Ian Rowe and Jeff McIntyre joined Roger Green to discuss key takeaways and impressions. In this conversation, the panelists focus on utilizing best practices in diagnostics.

This is truly an excellent podcast…(verified review) ⭐️⭐️⭐️⭐️⭐️
Read More
This is truly an excellent podcast. Roger Green is joined by Akero Therapeutics' Kitty Yale, Manal Abdelmalek (Duke University), Naim Alkhouri (Arizona Liver Health) and Stephen Harrison from Pinnacle Clinical Research. They go through the FDA's recent webcast and dissect the meaning and directions laid out. Interesting points around histology remaining the surrogate for the evaluation of NASH and how we need to have a better way of quantifying NASH histology
FINALLY!(verified review) ⭐️⭐️⭐️⭐️⭐️
Read More
A podcast for the NASH community! So many relevant topics. There are guest speakers almost every week who contribute a new energy to each episode. Keep up the good work coming!
I learn without trying(verified review) ⭐️⭐️⭐️⭐️⭐️
Read More
The host and other speakers are engaging to listen to yet not too serious or noting. I find mysweldf learning without trying. Excellent to have this on while working at home or driving while running errands.
At Long Last!(verified review) ⭐️⭐️⭐️⭐️⭐️
Read More
We have sorely needed a podcast that allows clinicians and academics to focus own major issues in NASH and NAFLD. Their recent coverage of ILC was timely and incisive. I find myself discussing the episodes with colleagues and Twitter buddies.
Previous
Next

Experience Nudge Learning! Interested in a new way of learning?